Varicella vaccine safety, incidence of breakthrough, and factors associated with breakthrough in Taiwan

American Journal of Infection Control

Volumn 31, Issue 3, 2003, Pages 151-156

  Tseng, Hung Fu ^a   Tan, Hsiu Fen ^b   Chang, Chen Kang ^a  

^a FOOYIN UNIVERSITY   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE;

ARTICLE; ATAXIA; CHICKENPOX; CHILD; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALITIS; FEVER; HUMAN; INFANT; INJECTION PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; RASH; TAIWAN; UPPER RESPIRATORY TRACT INFECTION;

EID: 0038053214     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1067/mic.2003.58     Document Type: Article

References (21)

1. Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001;344:955-60.
2. White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992;11:19-23.
3. Watson B, Gupta R, Randall T, Starr S. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine. J Infect Dis 1994;169:197-9.
4. Clements DA, Armstrong CB, Ursano AM, Moggio MM, Walter EB, Wilfert CM. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr Infect Dis J 1995;14:874-9.
5. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 1986;78:748-56.
6. Johnson C, Rome LP, Stancin T, Kumar ML. Humoral immunity and clinical reinfections following varicella vaccine in healthy children. Pediatrics 1989;84:418-21.
7. Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton DH, Neff BJ, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991;9:643-7.
8. Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000;284:1271-9.
9. Kanra G, Ceyhan M, Ozmert E. Safety and immunogenicity of live attenuated varicella vaccine in 9-month-old children. Pediatr Int 2000;42:674-7.
10. Ozaki T, Nishimura N, Kajita Y. Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic. Vaccine 2000;18:2375-80.
11. Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, et al. The postmarketing safety profile of varicella vaccine. Vaccine 2001;19:916-23.
12. Bernstein HH, Rothstein EP, Watson BM, Reisinger KS, Blatter MM, Wellman CO, et al. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 1993;92:833-7.
13. Balfour HH Jr, Kelly JM, Suarez CS, Heussner RC, Englund JA, Crane DD, et al. Acydovir treatment of varicella in otherwise healthy children. J Pediatr 1990;116:633-9.
14. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997;278:1495-9.
15. Watson BM, Piercy SA, Plotkin SA, Starr SE. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993;91:17-22.
16. Krause PR, Klinman DM, Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr 1995;127:518-25.
17. White CJ. Varicella-zoster virus vaccine. Clin Infect Dis 1997;24:753-61.
18. Zerboni L, Nader S,Aoki K,Arvin AM.Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis 1998;177:1701-4.
19. Johnson CE, Stancin T, Fattlar D, Rome LP, Kumar ML. A long-term prospective study of varicella vaccine in healthy children. Pediatrics 1997;100:761-6.
20. Arvin AM. Varicella vaccine - the first six years. N Engl J Med 2001;344:1007-9.
21. Black S, Shinefield H, Ray P, Lewis E, Hansen J, Schwalbe J, et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J 1999;18:1041-6.